About Oculeve
Oculeve is a Healthcare company based in San Francisco (United States) founded in 2011. A non-invasive nasal device for dry eye treatment is developed. Oculeve has raised $24.94 million across 4 funding rounds from investors including Kleiner Perkins, NEA and Versant Ventures. The company has 19 employees. The company has since been acquired. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its legal entity is OCULEVE, INC. Its competitors include TearScience, Tear Film Innovations and Bruder Healthcare; 3 of its 3 listed competitors have raised funding.
Company details
Oculeve is developing a treatment for dry eye disease. Its technology was conceptualized at Stanford University in a collaboration between the Departments of Biodesign and Ophthalmology. Its lead product is a non-invasive nasal neurostimulation device that increases tear production in patients with dry eye disease. The company was acquired by Allergan in July 2015 for a 125M upfront payment and milestone payments related to its lead development program.
- Headquarters San Francisco, United States
- Employees 19
- Stage Acquired
- SectorsHealthcare
- Website oculeve.com
- Social LinkedIn
- Legal Name Oculeve, Inc.
- Total Equity Funding$24.94M (USD)
in 4 rounds
- Latest Funding Round$16.65M (USD), Series B
Mar 2014
- InvestorsKleiner Perkins
& 3 more
- Employee Count19
Funding Insights of Oculeve
Oculeve has successfully raised a total of $24.94M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $16.65 million completed in March 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.94M
- Total Rounds 4
- Last Round Series B — $16.65M
- Investors Count 4
All 4 funding rounds of Oculeve with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2014 | $16.65M | Series B | – | – | – |
| Mar 2013 | $7.59M | Series A | – | – | |
| Aug 2012 | $700,000 | Seed | – | – | – |
| Jun 2010 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Oculeve
Oculeve has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, NEA and Versant Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Project-based bio-design courses are offered to Stanford graduates and post-docs. | biodesign.stanford.edu | Stanford, United States |
Investor details for Oculeve
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Oculeve
3 dated milestones of Oculeve across 4 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round.
- Founded Oculeve is founded.
- Funding Latest funding round, Series B, of $16.6M.
Competitors of Oculeve
Oculeve has 3 listed competitors in our database, 3 of them funded. They include TearScience, Tear Film Innovations and Bruder Healthcare.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tearscience.com | 2005 | Morrisville, United States | $150.73M | 35 | Devices for evaporative dry eye diagnosis and treatment are developed. | |
| tearfilm.com | 2012 | San Diego, United States | $17.72M | Evaporative dry eye is treated through meibomian gland stimulation devices. | ||
| bruder.com | 1986 | Alpharetta, United States | $5M | Solutions for dry eye and pain management are developed. |
Detailed competitors of Oculeve
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Oculeve (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oculeve
Complete news archive for Oculeve
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oculeve
Oculeve was founded in 2011.
Oculeve is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Oculeve is a funded company, having raised a total of $24.94M across 4 funding rounds to date.
Oculeve has 19 employees.
Oculeve is developing a treatment for dry eye disease. Its technology was conceptualized at Stanford University in a collaboration between the Departments of Biodesign and Ophthalmology. Its lead product is a non-invasive nasal neurostimulation device that increases tear production in patients with dry eye disease. The company was acquired by Allergan in July 2015 for a 125M upfront payment and milestone payments related to its lead development program.
Oculeve's top competitors include Tear Film Innovations, TearScience and Bruder Healthcare.
Oculeve has 4 investors. Key investors include Kleiner Perkins, NEA, Versant Ventures, and Stanford Biodesign.
Oculeve operates through Oculeve, Inc..